$2.89
3.21% yesterday
Nasdaq, May 20, 09:46 pm CET
ISIN
US68235C1071
Symbol
OCX

Oncocyte Corporation Stock price

$2.94
+0.06 2.08% 1M
+0.19 6.91% 6M
+0.56 23.53% YTD
+0.18 6.52% 1Y
-19.26 86.76% 3Y
-48.86 94.32% 5Y
-158.66 98.18% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.14 5.00%
ISIN
US68235C1071
Symbol
OCX
Sector

Key metrics

Market capitalization $84.08m
Enterprise Value $56.53m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.72
P/S ratio (TTM) P/S ratio 21.90
P/B ratio (TTM) P/B ratio 8.23
Revenue growth (TTM) Revenue growth 178.08%
Revenue (TTM) Revenue $3.84m
EBIT (operating result TTM) EBIT $-23.38m
Free Cash Flow (TTM) Free Cash Flow $-23.54m
Cash position $31.03m
EPS (TTM) EPS $-3.53
P/E forward negative
P/S forward 27.62
EV/Sales forward 18.57
Short interest 2.42%
Show more

Is Oncocyte Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Oncocyte Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Oncocyte Corporation forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Oncocyte Corporation forecast:

Buy
50%
Hold
50%

Financial data from Oncocyte Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.84 3.84
178% 178%
100%
- Direct Costs 3.44 3.44
55% 55%
90%
0.41 0.41
149% 149%
11%
- Selling and Administrative Expenses 13 13
11% 11%
331%
- Research and Development Expense 9.36 9.36
16% 16%
244%
-22 -22
7% 7%
-564%
- Depreciation and Amortization 1.72 1.72
12% 12%
45%
EBIT (Operating Income) EBIT -23 -23
7% 7%
-609%
Net Profit -58 -58
46% 46%
-1,516%

In millions USD.

Don't miss a Thing! We will send you all news about Oncocyte Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oncocyte Corporation Stock News

Neutral
GlobeNewsWire
one day ago
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the company's position in the growing transplant rejection testing market and suggests potential upside to its estimated $1 billion t...
Neutral
Seeking Alpha
8 days ago
OncoCyte Corporation (NASDAQ:OCX ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President & Chief Executive Officer Andrea James - Chief Financial Officer Ekke Schutz - Chief Science Officer Conference Call Participants Mark Massaro - BTIG Mason Carrico - Stephens Thomas Flaten - Lake Street Mike Mat...
Neutral
GlobeNewsWire
8 days ago
IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter results:
More Oncocyte Corporation News

Company Profile

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Head office United States
CEO Joshua Riggs
Employees 49
Founded 2009
Website www.oncocyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today